Lenalidomide Mylan 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
IB/0013/G 
This was an application for a group of variations. 
12/06/2023 
29/06/2023 
SmPC and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0011 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
04/10/2022 
SmPC and PL 
life of the finished product - As packaged for sale 
(supported by real time data) 
IAIN/0010/G 
This was an application for a group of variations. 
15/08/2022 
n/a 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
N/0009 
Minor change in labelling or package leaflet not 
15/07/2022 
Labelling and 
connected with the SPC (Art. 61.3 Notification) 
N/0008 
Minor change in labelling or package leaflet not 
28/02/2022 
08/07/2022 
connected with the SPC (Art. 61.3 Notification) 
IA/0007 
B.II.d.2.a - Change in test procedure for the finished 
06/10/2021 
n/a 
PL 
PL 
Page 2/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
product - Minor changes to an approved test 
procedure 
PSUSA/1838/
Periodic Safety Update EU Single assessment - 
22/07/2021 
16/09/2021 
Refer to Scientific conclusions and grounds recommending 
202012 
lenalidomide 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/1838/202012. 
IB/0006 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
13/09/2021 
08/07/2022 
SmPC 
To update section 6.3 of the Summary of Product 
life of the finished product - As packaged for sale 
Characteristics. 
(supported by real time data) 
IAIN/0005/G 
This was an application for a group of variations. 
13/08/2021 
08/07/2022 
Annex II and 
PL 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
IB/0004/G 
This was an application for a group of variations. 
19/07/2021 
12/08/2021 
SmPC, Annex 
II and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
Page 3/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0003/G 
This was an application for a group of variations. 
17/05/2021 
12/08/2021 
SmPC, 
Change in the pack size of the finished product outside the 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
Labelling and 
range of the currently approved pack size to add 7 x 1 
PL 
capsules in (PVC/Aclar/alu) unit dose blister for the 5 mg, 
10 mg & 15 mg strengths, new pack sizes of 7 x 1 capsules 
(unit dose) for the 2.5 mg, 7.5 mg, 20 mg & 25 mg 
strengths (EU/1/20/1490/019, EU/1/20/1490/021, 
EU/1/20/1490/025 and EU/1/20/1490/026) and new pack 
size of 7 capsules in blister (PVC/Aclar/alu) for the 10 mg 
strength (EU/1/20/1490/022).  
The marketing authorisation holder took the opportunity to 
align the PI to the latest QRD template (version 10.2) and 
to include editorial changes are in the linguistic versions of 
the Annexes for ES, HR and SK. 
Page 4/5 
 
 
 
 
 
 
 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
IA/0001 
A.7 - Administrative change - Deletion of 
05/03/2021 
12/08/2021 
SmPC, Annex 
manufacturing sites 
II and PL 
Page 5/5 
 
 
 
 
 
 
 
 
 
